RegeneRx has designed each formulation to serve a number of target disease indications within a broad area of interest. Each indication is supported by patents and research data, much of which have been published in peer-reviewed scientific and medical journals. Although RegeneRx cannot pursue all of these indications, partners have an opportunity to optimize indications that are important to their own therapeutic area of focus.
PRODUCT CANDIDATE |
TARGET INDICATION |
APPROXIMATE U.S. POPULATION/YEAR* |
RGN-259 (Tβ4 Eye Drop) |
Dry Eye Syndrome Neurotrophic Keratopathy (orphan) Recurrent Corneal Erosions Corneal Surgeries |
20M ~10K** 2.8M 1.3M |
RGN-352 (Tβ4 Injectable Solution) |
Acute Myocardial Infarction (AMI) Peripheral Neuropathy Stroke Traumatic Brain Injury (TBI) Multiple Sclerosis |
650K 15M 700K 500K 300K |
RGN-137 (Tβ4 dermal gel) |
Epidermolysis Bullosa (EB) Pressure and Venous Stasis Ulcers Scarring and Burns |
12K >3M TBD |
*Company estimates
**Stage 2 & 3, based on EU prevalence data and Clin Ophthalmol. 2014; 8: 571–579.